XCancer
Novartis

Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETs

Description:

This is a multicentre long-term non-interventional study of adult subjects diagnosed with unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive GEP-NETs who have been prescribed Lutathera® in standard clinical practice.

Sponsor:

Novartis

Contacts:

Novartis Pharmaceuticals (STUDY_DIRECTOR)

Government Study Link:

NCT04727723 - Click here to see study on

ClinicalTrials.gov

Oxodotreotide

Isotope(s):
Target(s):
  • SSTR2
Ligand Class: Peptides
Chelator: DOTA
Inclusion
  • Patients must be diagnosed with unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic-neuroendocrine tumour (GEP-NET).
  • Patients must be naïve to treatment with Lutathera® at enrolment.
Exclusion

Exclusion Criteria Not Yet Provided